Valuation Multiples by Industry: Healthcare Services, 2026
Medical Practice Valuation 2026 Guide
July 23, 2026
Professional buyers, including private equity firms, health systems, and strategic consolidators, typically value practices based on adjusted EBITDA and an applicable market multiple. While specialty and location influence that multiple, practice owners can strengthen value through five controllable factors: quality of earnings, scale, ancillary services, payer mix, and credible growth.
Because competitive buyer interest can drive stronger outcomes, practices should be brought to market through a structured process when the timing is right.
This article translates current market benchmarks into practical, table-driven insights. The ranges are guideposts, not guarantees. Ultimately, value depends on the quality of earnings demonstrated during diligence, as well as the dynamics of each transaction.
All valuation guidance is based on cited sources and internal knowledge. Actual pricing varies with each transaction and is based on many factors. Thus, information in this article is intended for educational purposes only and is not a guarantee of any outcome.
What you’ll learn in this article:
- Buyers base valuations on adjusted EBITDA, making clean financials and credible add-backs essential to proving earnings.
- Practices reaching $5M+ in EBITDA often qualify as platforms, earning significantly higher multiples than smaller add-ons.
- A strong commercial or cash-pay mix and owned ancillaries, such as ASCs or cath labs, can lift valuations by several turns.
- Multiples vary by specialty, with cardiology, ophthalmology, and gastroenterology leading the 2026 ranges.
- Early preparation (accurate financials, growth plans, and compliance readiness) remains the most reliable path to top-quartile outcomes.
Valuation Basics: Maximizing EBITDA and Multiples
Buyers pay for the enterprise value (EV) of a practice’s cash flows, typically on a last-twelve-months basis. Thus, normalization (owner comp resets, one-time expenses, and related-party adjustments) and an accurate EBITDA calculation is extremely important. Use this section as a quick formula reference.
EV ≈ Adjusted EBITDA × Multiple
What to normalize first:
- Reset above-market owner compensation to fair-market provider rates
- Remove personal/non-recurring expenses
- Align related-party rent to market, note any below-market leases ending soon
- Pro forma necessary hires (e.g., replacing a retiring producer) and de novo costs
- Consider pro forma revenue and EBITDA adjustments for new providers, new locations, payor changes, and similar growth initiatives
Valuation Approaches in Healthcare M&A
Medical practice value can be calculated in three ways:
| Market-Based Approach | Income-Based Approach | Asset-Based Approach |
| References recent sales of similar companies, typically applying EBITDA multiples used in comparable transactions. Most healthcare M&A transactions use this method. | Projects future cash flows and discounts them to present value. | Values tangible and intangible assets separately, subtracting liabilities. This is used for small or underperforming practices where earnings are limited or negative. |
Most physician and dental practice valuations use the first approach, focusing on recent transaction comps. Buyers may also consider the discounted cash flow model, especially when entering a new specialty.
Typical EBITDA Multiples by Healthcare Vertical (U.S., 2025–2026)
This table provides the starting point most buyers use when pricing deals. It consolidates observed ranges across six active healthcare services verticals.
| Healthcare sector | Typical EBITDA multiples | Notes that drive the range |
| Physician practices (medical) | ~5×–9× small and mid-sized groups; ~10×–12× for very large organizations | Can go higher for $5M+ EBITDA, diversified bench, ancillaries, dense coverage |
| Dental groups (DSO) | ~5×–11× | Premiums for multi-location pedo/ortho, OMS |
| Behavioral health | ~3×–8× small clinics; ~5×–10× mid-size/multi-site; low-teens for elite platforms | In-network mix, continuum of care, accreditation, multi-site, multi-state ops |
| Medical spa/aesthetics | ~3×–6× small; ~5×–8× mid-size; ~7×–12× scaled chains | Membership revenue, brand strength, and multi-state replication |
*Actual pricing varies with each transaction based on many factors. Intended for educational purposes only and not a guarantee of any outcome.
The Platform Premium by Size Band
Multiples don’t rise linearly with EBITDA: they tend to step-change at certain thresholds (often reflecting management depth, infrastructure, lender readiness, and other factors).
| Adjusted EBITDA | Typical buyer view | Cross-vertical valuation tendency |
| <$1M | Physician-to-physician or local tuck-in | Asset value to ~5×–6× |
| $1M–$3M | Add-on for an existing platform | ~5×–9× |
| $3M–$7M | Emerging platform with partial infrastructure | ~7×–11× |
| $7M+ | Established platform with scale and systems | ~9×–13×+ |
Payer Mix and Ancillaries: Levers That Move Your Multiple
Buyers price durability. Commercial and cash-pay revenue is more defensible than government-dependent books, and procedure-rich ancillaries lift margin and predictability.
| Factor | Directional impact on multiple | Why it moves value |
| ≥70% commercial or meaningful cash-pay | ↑ | Better rates, fewer denials, steadier collections |
| Heavy Medicaid / state funding | ↓ | Rate ceilings, budget risk |
| In-network vs out-of-network | ↑ for in-network | Contracted reimbursement is auditable and scalable |
| Owned ASC / surgery capacity | ↑ | Procedure margin stabilizes EBITDA |
| Ancillaries (imaging, lab, pharmacy) | ↑ | Revenue diversity and higher blended margin |
| Over-reliance on one star provider | ↓ | Concentration and succession risk |
What Pushes You to The High or Low End By Specialty
Every vertical has premium catalysts and discount flags. This table compiles the pattern recognition buyers commonly apply within each niche, allowing you to preempt issues in diligence and highlight strengths in your CIM.
| Vertical | Premium drivers | Common discounts |
| Physician groups | $3M+ EBITDA, diversified bench, dense referral base, ancillaries | Shrinking visits, single-doc reliance, reimbursement overhang |
| Dental (DSO) | Multi-location scale, pedo/ortho, OMS, strong hygiene recall, growth plan | Heavy Medicaid, flat production, owner-centric ops |
| Behavioral health | In-network mix, continuum of care, JCAHO/CARF, multi-state ops | OON dependence, staffing instability, regulatory history |
| Ophthalmology | ASC ownership, retina services, multiple MDs incl. younger partners | Senior partner concentration and succession issues |
| Women’s health | Imaging, surgery, fertility, midwifery, menopause programs | OB call burden without coverage, med-mal spikes |
| Medspa | Membership revenue, multi-market brand, de-novo playbook | Owner-operator dependence, transactional revenue only |
How Buyers Evaluate Risk and Upside
Buyers ultimately assess not just what a practice earns today, but how reliable and transferable those earnings are. In diligence, this typically comes down to consistent areas of focus:
| Evaluation Area | What Buyers Look For | Why It Matters |
| Earnings Quality | Clean financials, clear add-backs, consistent margins | Reduces uncertainty and supports valuation confidence |
| Provider Model | Defined roles, productivity visibility, and reduced single-provider reliance | Improves continuity post-transaction |
| Operational Structure | Documented workflows, scheduling discipline, billing visibility | Signals scalability and ease of integration |
| Growth Visibility | Clear expansion paths (providers, locations, services) | Supports forward-looking underwriting |
| Compliance & Documentation | Organized records, credentialing, and reporting | Minimizes diligence friction and delays |
This lens often explains why two practices with similar EBITDA can receive different valuations. The practice that is easier to understand, validate, and transition will generally command stronger buyer interest.
Common Gaps That Can Impact Valuation
Even strong practices can face valuation pressure if key areas are underdeveloped or unclear. The following issues are frequently encountered during the sale process:
- Unclear financial adjustments: Inconsistent or poorly documented add-backs can lead buyers to discount EBITDA or require additional diligence.
- Limited visibility into operations: Lack of reporting around scheduling, provider productivity, or case mix can make performance harder to validate.
- Overreliance on a single provider: Practices heavily dependent on one individual may raise concerns around continuity and transition risk.
- Informal or undefined growth plans: General ideas around expansion are less impactful than clearly outlined, actionable opportunities.
- Disorganized documentation: Missing or incomplete records can slow diligence and create avoidable friction late in the process.
Addressing these areas in advance can help maintain momentum, reduce buyer concerns, and support a more efficient transaction process.
How Buyers Underwrite, and Where You Can Influence Outcomes
This section explains why two similar practices can price far apart. Use it as a pre-diligence checklist to move your story from the middle to the top of the range.
What lifts your multiple:
- Profitability & scale: absolute EBITDA and margin quality
- Operational durability: payer diversity, referral stability, repeatable KPIs
- Growth clarity: funded de-novos, pipeline recruiting, and ancillaries with budgets
- Competitive tension: a process that reaches all logical buyers in your niche
- Strategic fit: solving a buyer’s footprint or service-line gap
What compresses it:
- Declining visits/production going into the process
- Unvetted add-backs or missing month-end discipline
- Concentration in one payer, producer, or referral source
Readiness Roadmap
Thinking of marketing in the next 6–12 months? These are the moves that consistently convert into higher headline multiples and fewer retrades. Treat them as a checklist you can execute with your advisors well before buyer outreach.
What to do now:
- Assemble 24–36 months of clean monthly financials with a defensible add-back schedule
- Package payer mix, denial rates, collections KPIs, and throughput metrics
- Build succession and recruiting plans for senior producers
- Map growth initiatives (de-novos, ancillaries, ASC) with capex and timelines
- Tighten compliance posture and accreditation; resolve any legacy issues
- Align related-party real estate to fair market terms
- Stand up a structured data room to control diligence
Putting It Together: Maximize EBITDA, Expand The Multiple, Protect Value
Valuation is the product of what you earn, how you earn it, and who is bidding. This article shows where your specialty tends to price; the levers and checklists show how to move up the curve. With thoughtful normalization, a crisp growth plan, and a competitive process targeting the right acquirers in your niche, it’s realistic to capture strong valuation outcomes, even in a cautious credit environment.
If you’d like more information, reach out to us here.
Sources:
- Eric Yetter (FOCUS Investment Banking), “How to Value a Medical Practice: What Really Matters,” FOCUS Bankers (July 31, 2023) focusbankers.com
- FOCUS Investment Banking – Healthcare Practice Management Updates (Ophthalmology 2024 Market Overview) focusbankers.com
- Chip Fichtner, Large Practice Sales – “2024 Results and 2025 Practice Values (Dental)” (Jan. 9, 2025) largepracticesales.com
- Scope Research – “Med Spa and Aesthetics Valuation Multiples and M&A Trends 2025,” (Updated Aug. 6, 2025) scoperesearch.co
- Scope Research – “Behavioral Health: SUD Treatment Valuation Multiples and Trends 2025,” (May 7, 2025) scoperesearch.co
- Scope Research – “Autism Services & Pediatric Therapy Valuation Multiples 2024,” (May 17, 2024) scoperesearch.co.
- Cascade Partners, Vision Care Market Update (Ophthalmology multiples by practice size, 2023) cascade-partners.com
- Physician Growth Partners, “State of Women’s Health Private Equity – Q1 2025” (White Paper) physiciangrowthpartners.com
- Solic Capital, “Physician Practice Management Q4 2020 Update” (Women’s Health platform valuations) soliccapital.com.
Written by
Eric Yetter
Managing Director
Eric Yetter is an investment banker focused on healthcare provider services. Eric has completed a variety of healthcare transactions, many with private equity firms and PE-backed companies. His past clients include leading physician and dental groups, behavioral health companies, healthcare facilities, and institutional healthcare investors.
View Bio
Written by
Managing Director
Related Insights
Let's connect
M&A guidance, backed by real experience
Whether you’re exploring a sale, raising capital, or simply want an outside perspective on where your business stands, our bankers are ready to listen. Reach out to start a confidential conversation with the FOCUS team.
